Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis
Journal of the American Academy of Dermatology | Sep 20, 2017
|Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Journal of the American Academy of Dermatology | Sep 20, 2017
Most read this week